These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 24118498)

  • 1. MYC translocation partner gene determines survival of patients with large B-cell lymphoma with MYC- or double-hit MYC/BCL2 translocations.
    Pedersen MØ; Gang AO; Poulsen TS; Knudsen H; Lauritzen AF; Nielsen SL; Klausen TW; Nørgaard P
    Eur J Haematol; 2014 Jan; 92(1):42-8. PubMed ID: 24118498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Double-hit BCL2/MYC translocations in a consecutive cohort of patients with large B-cell lymphoma - a single centre's experience.
    Pedersen MØ; Gang AO; Poulsen TS; Knudsen H; Lauritzen AF; Nielsen SL; Gang UO; Nørgaard P
    Eur J Haematol; 2012 Jul; 89(1):63-71. PubMed ID: 22510149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-L1 expression is low in large B-cell lymphoma with MYC or double-hit translocation.
    Elbaek MV; Pedersen MØ; Breinholt MF; Reddy A; Love C; Clasen-Linde E; Knudsen H; Nielsen SL; Gang AO; Høgdall E; Dave S; Nørgaard P
    Hematol Oncol; 2019 Oct; 37(4):375-382. PubMed ID: 31408531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stratification by MYC expression has prognostic impact in MYC translocated B-cell lymphoma-Identifies a subgroup of patients with poor outcome.
    Pedersen MØ; Gang AO; Clasen-Linde E; Breinholt MF; Knudsen H; Nielsen SL; Poulsen TS; Klausen TW; Høgdall E; Nørgaard P
    Eur J Haematol; 2019 May; 102(5):395-406. PubMed ID: 30737994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
    Green TM; Young KH; Visco C; Xu-Monette ZY; Orazi A; Go RS; Nielsen O; Gadeberg OV; Mourits-Andersen T; Frederiksen M; Pedersen LM; Møller MB
    J Clin Oncol; 2012 Oct; 30(28):3460-7. PubMed ID: 22665537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas.
    Pillai RK; Sathanoori M; Van Oss SB; Swerdlow SH
    Am J Surg Pathol; 2013 Mar; 37(3):323-32. PubMed ID: 23348205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma.
    Ye Q; Xu-Monette ZY; Tzankov A; Deng L; Wang X; Manyam GC; Visco C; Montes-Moreno S; Zhang L; Dybkær K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Parsons BM; Møller MB; Piris MA; Winter JN; Medeiros LJ; Hu S; Young KH
    Oncotarget; 2016 Jan; 7(3):2401-16. PubMed ID: 26573234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab.
    Perry AM; Alvarado-Bernal Y; Laurini JA; Smith LM; Slack GW; Tan KL; Sehn LH; Fu K; Aoun P; Greiner TC; Chan WC; Bierman PJ; Bociek RG; Armitage JO; Vose JM; Gascoyne RD; Weisenburger DD
    Br J Haematol; 2014 May; 165(3):382-91. PubMed ID: 24506200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Translocations involving the immunoglobulin heavy chain gene locus predict better survival in gastric diffuse large B-cell lymphoma.
    Nakamura S; Ye H; Bacon CM; Goatly A; Liu H; Kerr L; Banham AH; Streubel B; Yao T; Tsuneyoshi M; Savio A; Takeshita M; Dartigues P; Ruskoné-Fourmestraux A; Matsumoto T; Iida M; Du MQ
    Clin Cancer Res; 2008 May; 14(10):3002-10. PubMed ID: 18445693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance and prognosis of MYC translocation in diffuse large B-cell lymphoma.
    Zhang HW; Chen ZW; Li SH; Bai W; Cheng NL; Wang JF
    Hematol Oncol; 2011 Dec; 29(4):185-9. PubMed ID: 21692100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel IGH and MYC Translocation Partners in Diffuse Large B-Cell Lymphomas.
    Otto C; Scholtysik R; Schmitz R; Kreuz M; Becher C; Hummel M; Rosenwald A; Trümper L; Klapper W; Siebert R; Küppers R;
    Genes Chromosomes Cancer; 2016 Dec; 55(12):932-943. PubMed ID: 27356265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab.
    Barrans S; Crouch S; Smith A; Turner K; Owen R; Patmore R; Roman E; Jack A
    J Clin Oncol; 2010 Jul; 28(20):3360-5. PubMed ID: 20498406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does the proliferation fraction help identify mature B cell lymphomas with double- and triple-hit translocations?
    Mationg-Kalaw E; Tan LH; Tay K; Lim ST; Tang T; Lee YY; Tan SY
    Histopathology; 2012 Dec; 61(6):1214-8. PubMed ID: 23171357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional "hits" and outcomes with subsequent therapy.
    Epperla N; Maddocks KJ; Salhab M; Chavez JC; Reddy N; Karmali R; Umyarova E; Bachanova V; Costa C; Glenn M; Calzada O; Xavier AC; Zhou Z; Hossain NM; Hernandez-Ilizaliturri FJ; Al-Mansour Z; Barta SK; Chhabra S; Lansigan F; Mehta A; Jaglal MV; Evens AM; Flowers CR; Cohen JB; Fenske TS; Hamadani M; Costa LJ
    Cancer; 2017 Nov; 123(22):4411-4418. PubMed ID: 28749548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathological prognostic factors of 24 patients with B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma.
    Miyamoto K; Kobayashi Y; Maeshima AM; Taniguchi H; Nomoto J; Kitahara H; Fukuhara S; Munakata W; Maruyama D; Tobinai K
    Int J Hematol; 2016 Jun; 103(6):693-702. PubMed ID: 27095041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 'Double-Hit' cytogenetic status may not be predicted by baseline clinicopathological characteristics and is highly associated with overall survival in B cell lymphoma patients.
    Landsburg DJ; Nasta SD; Svoboda J; Morrissette JJ; Schuster SJ
    Br J Haematol; 2014 Aug; 166(3):369-74. PubMed ID: 24761809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BCL2 and MYC dual-hit lymphoma/leukemia.
    Tomita N
    J Clin Exp Hematop; 2011; 51(1):7-12. PubMed ID: 21628855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diffuse large B-cell lymphomas of immunoblastic type are a major reservoir for MYC-IGH translocations.
    Horn H; Staiger AM; Vöhringer M; Hay U; Campo E; Rosenwald A; Ott G; Ott MM
    Am J Surg Pathol; 2015 Jan; 39(1):61-6. PubMed ID: 25229766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type.
    Yoon SO; Jeon YK; Paik JH; Kim WY; Kim YA; Kim JE; Kim CW
    Histopathology; 2008 Aug; 53(2):205-17. PubMed ID: 18752503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study.
    Copie-Bergman C; Gaulard P; Leroy K; Briere J; Baia M; Jais JP; Salles GA; Berger F; Haioun C; Tilly H; Emile JF; Banham AH; Mounier N; Gisselbrecht C; Feugier P; Coiffier B; Molina TJ
    J Clin Oncol; 2009 Nov; 27(33):5573-9. PubMed ID: 19786664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.